Molnár Kinga Barbara
Klinikai Orvostudományok Doktori Iskola, Semmelweis Egyetem, Budapest, Hungary.
Magy Onkol. 2020 Mar 17;64(1):70-72. Epub 2019 Nov 21.
During colorectal cancer (CRC) development, in addition to genetic alterations, several epigenetic changes, including DNA methylation in the promoter regions accumulate in tumor cells. Cell-free DNA (cfDNA) in the circulatory system can originate also from tumor tissue; therefore the evaluation of methylated cfDNA in the plasma can be a promising method for early cancer screening. In my Ph.D., I have investigated the rate of cfDNA's release and stability using animal models. I aimed to compile an epigenetic marker panel, which contains genes with altered DNA methylation patterns in the healthy-colorectal adenoma-cancer sequence. I have found that the methylation level of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters has already increased in adenoma stages in both tissue and plasma samples. Immunohistochemistry analyses indicated decreasing protein expression in parallel with elevated methylation. According to our results, cfDNA amount and the methylation have been influenced by DNA isolation and blood collection methods.
在结直肠癌（CRC）发生发展过程中，除了基因改变外，肿瘤细胞还会积累多种表观遗传变化，包括启动子区域的DNA甲基化。循环系统中的游离DNA（cfDNA）也可源自肿瘤组织；因此，评估血浆中甲基化的cfDNA可能是一种很有前景的早期癌症筛查方法。在我的博士研究中，我使用动物模型研究了cfDNA的释放速率和稳定性。我的目标是编制一个表观遗传标记物面板，其中包含在健康-结直肠腺瘤-癌序列中DNA甲基化模式发生改变的基因。我发现，在腺瘤阶段，组织和血浆样本中SFRP1、SFRP2、SDC2和PRIMA1基因启动子的甲基化水平均已升高。免疫组织化学分析表明，蛋白质表达随着甲基化水平升高而降低。根据我们的结果，cfDNA的量和甲基化受到DNA分离和血液采集方法的影响。
